PD-1/PD-L1抑制剂在结直肠癌中的研究进展

Research progress of PD-1/PD-L 1 inhibitors for colorectal cancer

在过去10余年,尽管晚期结直肠癌(colorectal cancer,CRC)的总生存率得到明显改善,但晚期CRC仍然是全球恶性肿瘤死亡的主要原因之一。化疗和生物治疗是目前主要治疗策略。PD-1抑制剂在错配修复缺陷型转移性CRC患者中取得的成功引起了研究者对CRC免疫治疗的关注。近年来,PD-1抑制剂在CRC中的疗效已成为研究热点。本文就CRC免疫分型和分子水平变化概况对免疫检查点抑制剂的新型联合治疗方案进行综述。

Although the overall survival rate of colorectal cancer has been significantly improved over the last decade, advanced colorectal cancer remains one of the main causes of death from malignant tumors globally. Chemotherapeutic drugs and biological agents are the main therapeutic methods for colorectal cancer. The recent success in the discovery of programmed cell death protein1 （PD- 1） inhibitors in metastatic colorectal cancer patients with mismatch repair deficiency has generated overwhelming enthusiasm for its use in immunotherapy against the disease. In recent years, the efficacy of PD-1 inhibitors in colorectal cancer has become a hot top- ic. This review presents our current understanding of the immunophenotype and molecular changes in colorectal cancer and a novel combination therapy using inhibitors of the immune check-point.